Global elimination of hepatitis C virus infection: Progresses and the remaining challenges

Table 1 Profile of direct-acting antiviral agents[4,37,40,42,44,48-78]

Direct-acting antiviral agent	Generic name (abbreviation)	Code name	Trade name	Active against HCV genotype (based on clinical trial outcomes)	Combination therapy
NS3/4A protease inhibitors (-previr)	Telaprevir (TVR)	VX-950	Incivek/Incivo	1	TVR + IFN ± RBV
	Boceprevir (BOC)	SCH-503034 EBP-520	Victrelis	1	BOC + IFN ± RBV
	Faldaprevir (FDV)	BI-201335	-	1	FDV + Peg-IFN + RBV
	Simeprevir (SIM)	TMC-435	Olysio	1 and 4	SIM + SOF ± RBV
	Vaniprevir (VNV)	MK-7009	Vanihep	1	VNV + IFN ± RBV
	Asunaprevir (ASV)	BMS-650032	Sunvepra	1 and 4	ASV + DCV
	Paritaprevir (PTV)	ABT-450	Veruprevir	1 and 4	PTV+R+OBV+DAV ± RBV
	Voxilaprevir (VOX)	GS-9857	-	Pan-genotypic antiviral activity	VOX + SOF + VPR
	Sovaprevir	ACH-1625	-	1	Sovaprevir + ODV + RBV
	Grazoprevir (GZP)	MK-5172	-	1a, 1b, 4 and 6	Zepatier (GZP + EBV)
	Danoprevir (DNV)	RG-7227	-	1 and 4	DNV + PEG-IFN + RBV
		ITMN-191			DNV + R + PEG-IFN + RBV
		ASC08
	Deldeprevir (DDV)	ACH-2684 ACH-0142684	-	1	DDV + ODV
	Neceprevir
	Narlaprevir (NVR)	SCH-900518	Arlansa	1	NVR + R + PEG-IFN ± RBV
	Vedroprevir (VDV)	GS-9451	-	1	VDV + LDV + SOF
					VDV + LDV + TGV + RBV
	Glecaprevir (GLE)	ABT-493	-	Pan-genotypic antiviral activity	GLE + PIB ± RBV
	-	GS-9256	-	1	GS-9256 + PEG-IFN + RBV
					GS-9256 + TGV + Peg-IFN ± RBV
NS5A replication complex inhibitors (-Asvir)	Daclatasvir (DCV)	BMS-790052	Daklinza	1, 2 and 3	Sovodak (DCV + SOF) ± RBV
					DCV + VX-135
	Ledipasvir (LDV)	GS-5885	-	1, 3, 4, 5 and 6	Harvoni (LDV + SOF) ± RBV
					LDV + SOF ± (VDV or Radalbuvir)
	Ombitasvir (OBV)	ABT-267	-	1 and 4	Viekira Pak (OBV + PTV + R + DSV) ± RBV
					Technivie (OBV + PTV + R)
	Elbasvir (EBV)	MK-8742	-	1a, 1b, 4 and 6	Zepatier (EBV + GZP) ± RBV
	Velpatasvir (VPR)	GS-5816	-	Pan-genotypic antiviral activity	Epclusa (VPR + SOF) ± RBV
	Odalasvir (ODV)	ACH-3102	-	1	ODV + Sovaprevir + RBV
	Ravidasvir (RVD)	PPI-668	-	4	RVD + SOF ± RBV
		ASC16
	-	PPI-461	-	1	-
	-	JNJ-56914845	-	1	GSK2336805 + PEG-IFN + RBV
		GSK2336805			GSK2336805 + VX-135 + SIM
	Samatasvir	IDX-18719 IDX-719	-	1, 2, 3 and 4	Samatasvir + SIM + RBV
		MK-1894
	-	BMS-824393	-	1	BMS-824393 + PEG-IFN + RBV
	Pibrentasvir (PIB)	ABT-530	-	Pan-genotypic antiviral activity	PIB + GLE ± RBV
	Ruzasvir (RZR)	MK-8408	-	Pan-genotypic antiviral activity	RZR + UPR + GZP
Nucleoside NS5B polymerase inhibitors	Sofosbuvir (SOF)	PSI-7977;	Sovaldi; Soforal	Pan-genotypic antiviral activity	SOF + IFN ± RBV
(-Buvir)		GS-7977			Sovodak (DCV + SOF) ± RBV
	Mericitabine (MCB)	RG-7128	-	1 and 4	MCB + PEG-IFN + RBV
		RO5024048			MCB + DNV
					MCB + R + DNV ± RBV
	-	VX-135	-	1	VX-135 + GSK2336805 + SIM
		ALS-2200			VX-135 + TVR + RBV
					VX-135 + DCV
					VX-135 + RBV
					VX-135 + SIM
	Valopicitabine	NM283	-	1	Valopicitabine + Peg-IFN
Non-nucleoside NS5B polymerase inhibitors (-Buvir)	Beclabuvir (BCV)	BMS-791325	-	1	BCV+ ASV+ DCV
	Dasabuvir (DAV)	ABT-333	Exviera	1	DAV + OBV+ PTV + R ± RBV
	Lomibuvir	VX-222	-	1	VX-222 + TVR + RBV
		VCH-222			VX-222 + Filibuvir
	Filibuvir	PF-00868554,	-	1	Filibuvir + Peg-IFN + RBV
		PF-868554			Filibuvir + VX-222
	Setrobuvir (STV)	ANA-598	-	1	STV + IFN + RBV
		RO-5466731			STV + R + DNV + RBV ± MCB
		RG-7790
	Nesbuvir (NBV)	HCV-796	-	1	NBV +Peg-IFN + RBV
		VB-19796
	Tegobuvir (TGV)	GS-9190	-	1	TGV + GS-9256 +Peg-IFN ± RBV
					TGV + LDV + VDV + RBV
	Deleobuvir (DBV)	BI-207127	-	1	DBV + PEG-IFN + RBV
					DBV + FDV
					DBV + FDV + RBV
	Uprifosbuvir (UPR)	MK-3682	-	Pan-genotypic antiviral activity	UPR + RZR
					UPR + RZR + GZP
	Radalbuvir	GS-9669	-	1	Radalbuvir + LDV + SOF
	AL-335	ALS-335	-	1	AL-335 + ODV + SIM

IFN: Interferon; RBV: Ribavirin; R: Ritonavir; PEG-IFN: Pegylated interferon.